Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.

被引：0
|
作者：
Small, Eric Jay
Saad, Fred
Rathkopf, Dana E.
Hadaschik, Boris A.
Chowdhury, Simon
Yu, Margaret K.
Lopez-Gitlitz, Angela
Rooney, Oliver Brendan
Shu, Youyi
Darif, Mohamed
Smith, Matthew Raymond
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Montreal, Ctr Hosp Univ Montreal CRCHUM, Montreal, PQ, Canada
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Univ Duisburg Essen, Essen, Germany
[6] Guys Kings & St Thomas Hosp, London, England
[7] Janssen Res & Dev, Los Angeles, CA USA
[8] Janssen Res & Dev, High Wycombe, Bucks, England
[9] Janssen Res & Dev, Collegeville, PA USA
[10] Janssen Res & Dev, San Diego, CA USA
[11] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[12] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5034
引用
收藏
页数：2
相关论文
共 50 条
  • [21] DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Briganti, Alberto
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Suzuki, Hiroyoshi
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Guan, Rongjin
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] EFFICACY AND SAFETY OF APALUTAMIDE (APA) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH OR WITHOUT PRIOR RADICAL PROSTATECTOMY (RP) AND/OR EXTERNAL RADIOTHERAPY (XRT): POST HOC ANALYSIS OF SPARTAN
    Hadaschik, Boris A.
    Saad, Fred
    Graff, Julie N.
    Olmos, David
    Oudard, Stephane
    Mainwaring, Paul N.
    Uemura, Hiroji
    Lee, Ji Youl
    Lopez-Gitlitz, Angela
    Bhaumik, Amitabha
    Londhe, Anil
    Cheng, Shinta
    Todd, Mary B.
    Small, Eric J.
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2019, 201 (04): : E502 - E503
  • [23] Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
    Cattrini, Carlo
    Caffo, Orazio
    De Giorgi, Ugo
    Mennitto, Alessia
    Gennari, Alessandra
    Olmos, David
    Castro, Elena
    CANCERS, 2022, 14 (07)
  • [24] Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study
    Fizazi, K.
    Shore, N.
    Smith, M.
    Carles, J.
    Lebret, T.
    Lietuvietis, V.
    Mahammedi, H.
    Rannikko, A.
    Vjaters, E.
    Werbrouck, P.
    Miskic, M.
    Kuss, I.
    Le Berre, M.
    Borghesi, G.
    Sarapohja, T.
    Fayerabend, S.
    EUROPEAN UROLOGY, 2021, 79 : S1740 - S1741
  • [25] Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study
    Krabbe, L. -M
    Fizazi, K.
    Shore, N.
    Smith, M.
    Carles, J.
    Lebret, T.
    Lietuvietis, V
    Mahammedi, H.
    Rannikko, A.
    Vjaters, E.
    Werbrouck, P.
    Miskic, M.
    Kuss, I
    Le Berre, M. A.
    Borghesi, G.
    Sarapohja, T.
    Feyerabend, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 265 - 265
  • [26] Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)
    Mainwaring, P.
    Small, E.
    Saad, F.
    Chowdhury, S.
    Oudard, S.
    Hadaschik, B.
    Graff, J.
    Olmos, D.
    Lee, J.
    Uemura, H.
    Lopez-Gitlitz, A.
    Espina, B.
    Shu, Y.
    Rackoff, W.
    Rooney, B.
    Londhe, A.
    Cheng, S.
    Smith, M.
    BJU INTERNATIONAL, 2019, 123 : 46 - 47
  • [27] DISEASE SPECIFIC COST ANALYSIS OF THE NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATES
    Yanev, I
    Aprikian, A.
    Nablsi, E.
    Primiani, J.
    Vaillancourt, Z.
    Dragomir, A.
    VALUE IN HEALTH, 2018, 21 : S73 - S73
  • [28] Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Small, Eric Jay
    Saad, Fred
    Chowdhury, Simon
    Oudard, Stephane
    Hadaschik, Boris A.
    Graff, Julie Nicole
    Olmos, David
    Mainwaring, Paul N.
    Lee, Ji Youl
    Uemura, Hiroji
    Lopez-Gitlitz, Angela
    Espina, Byron M.
    Shu, Youyi
    Rackoff, Wayne R.
    Rooney, Oliver Brendan
    Londhe, Anil
    Cheng, Shinta
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [29] THIRD INTERIM ANALYSIS (IA3) OF THE DAROLUTAMIDE OBSERVATIONAL (DAROL) STUDY IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
    Gotto, Geoffrey
    Suzuki, Hiroyoshi
    Luz, Murilo
    Briganti, Alberto
    Yu, Evan Y.
    Pieczonka, Christopher
    Murphy, Declan
    Malone, Ryan
    Hamilton, Joelle
    Chan, Jonathan E.
    Sieber, Paul
    Given, Robert W.
    Adorjan, Patrick
    Ghadessi, Mercedeh
    Verholen, Frank
    Armstrong, Andrew J.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E63 - E63
  • [30] Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
    Clarke, Noel
    Wiechno, Pawel J.
    Alekseev, Boris
    Sala, Nuria
    Jones, Robert
    Kocak, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345